Second cancers in Hodgkin's lymphoma long-term survivals: A
60-year single institutional experience with real-life cohort
of 871 patients

J 2018

Second cancers in Hodgkin's lymphoma long-term survivals: A 60-year single institutional experience with real-life cohort of 871 patients

PETRÁKOVÁ, Katarína, Jiří VYSKOČIL, Peter GRELL, Ondřej MÁJEK, Renata SOUMAROVÁ et. al.

Základní údaje

Originální název

Second cancers in Hodgkin's lymphoma long-term survivals: A 60-year single institutional experience with real-life cohort of 871 patients

Autoři

PETRÁKOVÁ, Katarína (203 Česká republika, domácí), Jiří VYSKOČIL (203 Česká republika), Peter GRELL (703 Slovensko, domácí), Ondřej MÁJEK (203 Česká republika, domácí), Renata SOUMAROVÁ (203 Česká republika), Jiri NOVAK (203 Česká republika), Petr BURKOŇ (203 Česká republika, domácí), Zdeněk KRÁL (203 Česká republika), Tomáš KAZDA (203 Česká republika, garant, domácí) a Rostislav VYZULA (203 Česká republika, domácí)

Vydání

International Journal of Clinical Practice, HOBOKEN, Medicom International, 2018, 1368-5031

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.613

Kód RIV

RIV/00216224:14110/18:00104491

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1111/ijcp.13235

UT WoS

000441884600001

Klíčová slova anglicky

Hodgkin's lymphoma

Štítky

14110811, 14110812, 14119612, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 8. 3. 2019 13:09, Mgr. Pavla Foltynová, Ph.D.

Anotace

V originále

Background and Purpose: Appropriate surveillance guidelines for patients after successful treatment of Hodgkin's lymphoma (HL) are needed to reduce mortality of iatrogenic secondary cancers (SC). This large single institutional retrospective study analyses the risk of SC in HL patients treated outside of clinical trials over past decades. Material and Methods: Consecutive series of HL patients were analysed with median follow-up 12years. Standardised incidence ratio (SIR) and absolute excess risk (AER) were calculated for site-specific risk of SC. Results: In total of 871 patients (491 men; median age 34years), chemotherapy alone, radiotherapy alone, and combined treatment underwent 36%, 40%, and 24% patients. 154 SC were found with significantly increased SIR=2.9 and AER=80.8 for all cancers except of nonmelanoma-skin cancer. SC-related death occurred in 71 patients (15% of those who died, 8% of whole cohort). The most common SC were lung (17.5% of all malignancies, SIR=3.2), breast carcinoma (15.6%, SIR=4.4), and haematological malignancy (non-Hodgkin's lymphoma SIR=13.1; leukaemia SIR=5.8). For SC within radiation field, the highest AER was in breast (AER=46.9), colorectal (AER=22.8), and lung cancer (AER=17). Conclusions: Patients with HL are generally at great risk of developing SC, which is significantly increased especially by the use of radiotherapy. We suggested special follow-up schema for patients after initial HL treatment suitable for daily real-world clinical practice. The system depends on gender, form of HL treatment and especially the form of radiation therapy in terms of location of radiation fields.

Návaznosti

LQ1601, projekt VaV

Název: CEITEC 2020 (Akronym: CEITEC2020)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CEITEC 2020

Citovat

PETRÁKOVÁ, Katarína, Jiří VYSKOČIL, Peter GRELL, Ondřej MÁJEK, Renata SOUMAROVÁ, Jiri NOVAK, Petr BURKOŇ, Zdeněk KRÁL, Tomáš KAZDA a Rostislav VYZULA. Second cancers in Hodgkin's lymphoma long-term survivals: A 60-year single institutional experience with real-life cohort of 871 patients. International Journal of Clinical Practice. HOBOKEN: Medicom International, 2018, roč. 72, č. 9, s. 1-9. ISSN 1368-5031. Dostupné z: https://dx.doi.org/10.1111/ijcp.13235.

@article{1468657,
   author = {Petráková, Katarína and Vyskočil, Jiří and Grell, Peter and Májek, Ondřej and Soumarová, Renata and Novak, Jiri and Burkoň, Petr and Král, Zdeněk and Kazda, Tomáš and Vyzula, Rostislav},
   article_location = {HOBOKEN},
   article_number = {9},
   doi = {http://dx.doi.org/10.1111/ijcp.13235},
   keywords = {Hodgkin's lymphoma},
   language = {eng},
   issn = {1368-5031},
   journal = {International Journal of Clinical Practice},
   title = {Second cancers in Hodgkin's lymphoma long-term survivals: A 60-year single institutional experience with real-life cohort of 871 patients},
   volume = {72},
   year = {2018}
}

TY  - JOUR
ID  - 1468657
AU  - Petráková, Katarína - Vyskočil, Jiří - Grell, Peter - Májek, Ondřej - Soumarová, Renata - Novak, Jiri - Burkoň, Petr - Král, Zdeněk - Kazda, Tomáš - Vyzula, Rostislav
PY  - 2018
TI  - Second cancers in Hodgkin's lymphoma long-term survivals: A 60-year single institutional experience with real-life cohort of 871 patients
JF  - International Journal of Clinical Practice
VL  - 72
IS  - 9
SP  - 1-9
EP  - 1-9
PB  - Medicom International
SN  - 13685031
KW  - Hodgkin's lymphoma
N2  - Background and Purpose: Appropriate surveillance guidelines for patients after successful treatment of Hodgkin's lymphoma (HL) are needed to reduce mortality of iatrogenic secondary cancers (SC). This large single institutional retrospective study analyses the risk of SC in HL patients treated outside of clinical trials over past decades. Material and Methods: Consecutive series of HL patients were analysed with median follow-up 12years. Standardised incidence ratio (SIR) and absolute excess risk (AER) were calculated for site-specific risk of SC. Results: In total of 871 patients (491 men; median age 34years), chemotherapy alone, radiotherapy alone, and combined treatment underwent 36%, 40%, and 24% patients. 154 SC were found with significantly increased SIR=2.9 and AER=80.8 for all cancers except of nonmelanoma-skin cancer. SC-related death occurred in 71 patients (15% of those who died, 8% of whole cohort). The most common SC were lung (17.5% of all malignancies, SIR=3.2), breast carcinoma (15.6%, SIR=4.4), and haematological malignancy (non-Hodgkin's lymphoma SIR=13.1; leukaemia SIR=5.8). For SC within radiation field, the highest AER was in breast (AER=46.9), colorectal (AER=22.8), and lung cancer (AER=17). Conclusions: Patients with HL are generally at great risk of developing SC, which is significantly increased especially by the use of radiotherapy. We suggested special follow-up schema for patients after initial HL treatment suitable for daily real-world clinical practice. The system depends on gender, form of HL treatment and especially the form of radiation therapy in terms of location of radiation fields.
ER  -

PETRÁKOVÁ, Katarína, Jiří VYSKOČIL, Peter GRELL, Ondřej MÁJEK, Renata SOUMAROVÁ, Jiri NOVAK, Petr BURKOŇ, Zdeněk KRÁL, Tomáš KAZDA a Rostislav VYZULA. Second cancers in Hodgkin's lymphoma long-term survivals: A 60-year single institutional experience with real-life cohort of 871 patients. \textit{International Journal of Clinical Practice}. HOBOKEN: Medicom International, 2018, roč.~72, č.~9, s.~1-9. ISSN~1368-5031. Dostupné z: https://dx.doi.org/10.1111/ijcp.13235.

Podrobný výpis o publikaci